China's space station, Tiangong, is set to offer a groundbreaking insight into fatty liver treatment through an experiment that has just concluded. This seven-day study aboard the station focused on the effects of space-associated biological phase separation on lipid metabolism under microgravity conditions, shedding light on the complex relationship between space and liver health.
The experiment, led by Li Ning, an associate researcher at the Institute of Mechanics of the Chinese Academy of Sciences, delves into the impact of microgravity on liver cells, specifically hepatocytes. The liver's intricate mechanical micro-environment, which is altered during diseases like liver fibrosis and fatty liver disease, is a key area of interest.
One of the critical factors in this study is fluid shear stress, which is significantly affected by the unique conditions of space. In normal conditions, blood flow through the liver's blood vessels creates interstitial shear stress, maintaining metabolic homeostasis. However, in microgravity, the redistribution of body fluids leads to a decrease in portal venous blood flow to the liver, reducing the mechanical effect of blood flow on the liver.
This reduction in blood flow shear stress has a direct impact on the liver's metabolic functions. The study found that the microgravity environment activated the SREBP protein, leading to an increase in intracellular lipid droplets. Conversely, blood flow inhibits the SREBP protein, exerting a protective effect by reducing lipid droplets.
The experiment's design included a unique intervention group that simulated the mechanical stimulation from blood flow, enhancing cellular responses. This approach is significant because it builds upon previous studies confirming the protective effect of the blood flow environment on cells.
The in-orbit experiment utilized hepatocytes as the research subject, with three experimental conditions: static culture, simulated blood flow environment, and a 'blood flow environment with drug stimulation'. This resulted in six cell samples, each contributing valuable data.
The experiment was remotely controlled by ground-based researchers, who performed daily microscopic imaging to observe cell growth in real-time. On the seventh day, a fixative solution was automatically injected to preserve the cellular state, and the samples were stored at -80 degrees Celsius.
The samples are expected to return to Earth in the second half of the year, marking the beginning of a comprehensive data analysis phase. This study not only highlights the potential of space research in medical advancements but also opens up new avenues for understanding and treating fatty liver disease.
